Statins (unspecified)
What studies of statins (unspecified) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, compared with another group, not randomised (very low certainty), for daily functioning.
1 outcome rated · see each below
Preventing long COVID: D Little or no difference
Based on the strongest evidence, compared with another group, not randomised (very low certainty): 3 of 4 findings are D.
4 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, statins (unspecified) might help some people, but research can’t show it yet. For preventing long COVID, studies found little or no difference with statins (unspecified). If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Statins (unspecified) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Statins (unspecified) · Preventing long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Daily life and health overall
Daily functioning1 study · 54 people took statins (unspecified) Improvement C
Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); not all results were tested against chance.
Compared with another group, not randomised104 in the study · 88 with outcome data
Daily functioning improved more than in the comparison group.
The evidence is very uncertain about the effect of statins (unspecified) on daily functioning in long COVID. Improvement · very low certainty C
- Serious risk of bias (ROBINS-I)
- Not all results were tested against chance
See the 1 study
-
THE INFLUENCE OF STATIN USE ON AUTONOMIC MODULATION AND FUNCTIONAL CAPACITY OF ELDERLY IN POST-COVID-19 SYNDROME (2024)
- People in the study
- 104 in the study · 88 with outcome data
- Dose
- —
- Outcome
- Flexão de cotovelo (rep) teste de Flexão de cotovelo
- Effect
- better (not tested)
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- Moderate. comparison group: grupos alocados conforme uso de medicação e diagnóstico de COVID-19; amostragem não probabilística
alocados conforme o uso de medicação e diagnóstico de COVID19
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: 16 participantes não puderam comparecer nas datas previstas devido a doença ou desistência; 88 avaliados
16 participantes não puderam comparecer nas datas previstas devido a doença ou desistência
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Preventing long COVID
Breathlessness1 study · 176 people took statins (unspecified) Improvement C
Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); effect size 0.37 (small).
Compared with another group, not randomised518 in the study · days 28 and 90 after presenting initial symptoms on day 0
Breathlessness improved more than in the comparison group.
The evidence is very uncertain about the effect of statins (unspecified) on breathlessness later, when given during acute COVID. Improvement · very low certainty C
- Serious risk of bias (ROBINS-I)
- Effect size 0.37 (small)
How big was the difference?
0.37, small. The effect size compares statins (unspecified) with non-statin group.
See the 1 study
-
- People in the study
- 518 in the study
- Dose
- —
- Outcome
- Dyspnea
- Effect
- better
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. comparison group: Non-statin group was patients not receiving statins; propensity score matching was performed.
Covariates in the propensity analyses included age, sex, obesity, Charlson comorbidity index, smoking status, use of insulin, diabetes duration, serum level of glycosylated hemoglobin, history of liver disease, renal disease, hypertension, cardiovascular disease, and cerebrovascular disease.
- Selection of participants
- Moderate. comparison group: Non-statin group was patients not receiving statins; propensity score matching was performed.
COVID-19 patients with diabetes who met the inclusion criteria were included in Statin or Non-statin groups
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Follow-up attendance: 176 out of 263 in the Statin group and 206 out of 255 in the Non-statin group attended first and second follow-up interviews; after propensity matching, 176 patients from each group were included in data analysis; HRCT analysis included 51 statin and 42 non-statin patients with both initial and follow-up scans.
A hundred and seventy-six out of 263 patients in the Statin group and 206 out of 255 patients in the Non-statin group successfully attended the first and second follow-up interviews.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Fatigue1 study · 176 people took statins (unspecified) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance; effect size 0.00 (very small).
Compared with another group, not randomised518 in the study · days 28 and 90 after presenting initial symptoms on day 0
No clear difference in fatigue.
The evidence is very uncertain about the effect of statins (unspecified) on fatigue later, when given during acute COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- The change wasn't shown to be more than chance
- Effect size 0.00 (very small)
How big was the difference?
0, very small. The effect size compares statins (unspecified) with non-statin group.
See the 1 study
-
- People in the study
- 518 in the study
- Dose
- —
- Outcome
- Fatigue
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. comparison group: Non-statin group was patients not receiving statins; propensity score matching was performed.
Covariates in the propensity analyses included age, sex, obesity, Charlson comorbidity index, smoking status, use of insulin, diabetes duration, serum level of glycosylated hemoglobin, history of liver disease, renal disease, hypertension, cardiovascular disease, and cerebrovascular disease.
- Selection of participants
- Moderate. comparison group: Non-statin group was patients not receiving statins; propensity score matching was performed.
COVID-19 patients with diabetes who met the inclusion criteria were included in Statin or Non-statin groups
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Follow-up attendance: 176 out of 263 in the Statin group and 206 out of 255 in the Non-statin group attended first and second follow-up interviews; after propensity matching, 176 patients from each group were included in data analysis; HRCT analysis included 51 statin and 42 non-statin patients with both initial and follow-up scans.
A hundred and seventy-six out of 263 patients in the Statin group and 206 out of 255 patients in the Non-statin group successfully attended the first and second follow-up interviews.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Pain1 study · 176 people took statins (unspecified) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance; effect size 0.00 (very small).
Compared with another group, not randomised518 in the study · days 28 and 90 after presenting initial symptoms on day 0
No clear difference in pain.
The evidence is very uncertain about the effect of statins (unspecified) on pain later, when given during acute COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- The change wasn't shown to be more than chance
- Effect size 0.00 (very small)
How big was the difference?
0, very small. The effect size compares statins (unspecified) with non-statin group.
See the 1 study
-
- People in the study
- 518 in the study
- Dose
- —
- Outcome
- Myalgia/arthralgia
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. comparison group: Non-statin group was patients not receiving statins; propensity score matching was performed.
Covariates in the propensity analyses included age, sex, obesity, Charlson comorbidity index, smoking status, use of insulin, diabetes duration, serum level of glycosylated hemoglobin, history of liver disease, renal disease, hypertension, cardiovascular disease, and cerebrovascular disease.
- Selection of participants
- Moderate. comparison group: Non-statin group was patients not receiving statins; propensity score matching was performed.
COVID-19 patients with diabetes who met the inclusion criteria were included in Statin or Non-statin groups
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Follow-up attendance: 176 out of 263 in the Statin group and 206 out of 255 in the Non-statin group attended first and second follow-up interviews; after propensity matching, 176 patients from each group were included in data analysis; HRCT analysis included 51 statin and 42 non-statin patients with both initial and follow-up scans.
A hundred and seventy-six out of 263 patients in the Statin group and 206 out of 255 patients in the Non-statin group successfully attended the first and second follow-up interviews.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Smell and taste loss1 study · 176 people took statins (unspecified) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance; effect size 0.00 (very small).
Compared with another group, not randomised518 in the study · days 28 and 90 after presenting initial symptoms on day 0
No clear difference in smell and taste loss.
The evidence is very uncertain about the effect of statins (unspecified) on smell and taste loss later, when given during acute COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- The change wasn't shown to be more than chance
- Effect size 0.00 (very small)
How big was the difference?
0, very small. The effect size compares statins (unspecified) with non-statin group.
See the 1 study
-
- People in the study
- 518 in the study
- Dose
- —
- Outcome
- Anosmia/ageusia
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. comparison group: Non-statin group was patients not receiving statins; propensity score matching was performed.
Covariates in the propensity analyses included age, sex, obesity, Charlson comorbidity index, smoking status, use of insulin, diabetes duration, serum level of glycosylated hemoglobin, history of liver disease, renal disease, hypertension, cardiovascular disease, and cerebrovascular disease.
- Selection of participants
- Moderate. comparison group: Non-statin group was patients not receiving statins; propensity score matching was performed.
COVID-19 patients with diabetes who met the inclusion criteria were included in Statin or Non-statin groups
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Follow-up attendance: 176 out of 263 in the Statin group and 206 out of 255 in the Non-statin group attended first and second follow-up interviews; after propensity matching, 176 patients from each group were included in data analysis; HRCT analysis included 51 statin and 42 non-statin patients with both initial and follow-up scans.
A hundred and seventy-six out of 263 patients in the Statin group and 206 out of 255 patients in the Non-statin group successfully attended the first and second follow-up interviews.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Side effects
No study of this treatment alone reported side effects we could read.
All papers
- THE INFLUENCE OF STATIN USE ON AUTONOMIC MODULATION AND FUNCTIONAL CAPACITY OF ELDERLY IN POST-COVID-19 SYNDROME2024 · compared with another group · 104 in the study · 88 with outcome data
Summary
This cross-sectional, quantitative, analytical, exploratory study asked whether statin use influences autonomic modulation and functional capacity in older adults with post-COVID-19 syndrome. It was conducted at the Centro de Atenção Integrada do Idoso (CAISI) and the Universidade Ceuma bodybuilding gym. Of 104 eligible older adults, 16 did not attend scheduled dates; the stated reasons were illness or dropout. The paper reports 88 analysed: no COVID/no statins n=16; statins/no COVID n=14; COVID/no statins n=18; COVID/statins n=40. Statin use was 3,94±2,91 years in the statin group and 4,0±2,92 years in the COVID/statins group; no significant difference in duration was reported (p=0,540). Groups were compared using heart-rate variability and functional tests (sit-to-stand five times, elbow flexion, Timed Up and Go). Significant between-group differences were reported for Mean RR (p<0,001), SDNN (p<0,001), Mean HR (p<0,001), RMSSD (p<0,001), LF/HF ratio (p<0,001), Total power (p=0,010), TLS5v (p=0,020), elbow flexion (p<0,001), and TUG (p<0,001). RMSSD was lower in COVID/no statins (14,74) and higher in COVID/statins (24,02); LF/HF ratio was higher in COVID/no statins (1,44). Elbow flexion repetitions were higher in COVID/statins (14), and TUG time was shortest in statins/no COVID (6,56). Side effects were not reported. The authors state results should be interpreted with caution given the nature of the study.
- The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study.2023 · compared with another group · 518 in the study
Summary
This multi-center prospective cohort study asked whether statins affect long-term respiratory symptoms and pulmonary fibrosis in COVID-19 patients with diabetes mellitus in three tertiary hospitals in Iran. After exclusions, 518 patients were included; after propensity matching, 176 patients from each group were included in data analysis. The statin group received atorvastatin (148), rosuvastatin (17), simvastatin (8), or other statins (3); the non-statin group received no statin. Follow-up was three months after initial symptoms, with interviews on days 28 and 90. Cough and dyspnea frequencies were compared. The odds of cough were higher in the non-statin group (OR 1.35, 95% CI 1.01–1.81; p = 0.046), and the odds of dyspnea were higher (OR 1.42, 95% CI 1.02–1.98; p = 0.037). Time to cough resolution favored the statin group (HR 0.68, 95% CI 0.48–0.94; p = 0.016); there were no significant differences for time to symptom-free dyspnea or chest pain, or for CSS/mMRC scores (p > 0.05 for all). Pulmonary fibrosis score showed no significant between-group difference (β = 1.225, 95% CI –0.47–2.92; p = 0.15), based on 51 statin and 42 non-statin patients with HRCTs; a subgroup with diabetes duration >5 years had a between-group difference (β = 2.43, 95% CI 0.12–4.74; p = 0.041). Harms and withdrawals were not reported. The authors state that the fibrosis finding may be related to the relatively low number of assessed HRCTs.
- Beyond Antivirals: Alternative Therapies for Long COVID.2024 · review
Summary
This scoping review searched PubMed from January 2021 to September 2024 and included 18 studies of non-antiviral treatments for Long COVID/PASC. The review itself had no comparison group and was not randomized; the included evidence came from randomized trials, observational research, and case series. Treatment duration was not reported. Reported findings included metformin in two phase 3 trials with reductions in Long COVID incidence of 42% to 63%; LDN with over 50% of participants reporting cognitive improvements and a five-fold higher likelihood of improvement compared with physical therapy alone; dexamethasone with a 33% reduction in fatigue and median symptom duration of 133 days vs. 271 days; omega-3 fatty acids in 33,908 patients with moderate improvements in mental health and musculoskeletal symptoms; L-arginine plus vitamin C with 94.9% reporting absence of fatigue and 74.2% no dyspnea; therapeutic apheresis with significant improvements in 70% of 27 patients; and IVIg with improved fatigue and cognitive dysfunction in 70–75% of patients. NAC improved cognitive function in 67% of 12 patients but had a 25% discontinuation rate due to side effects; a small percentage discontinued LDN due to mild side effects such as fatigue and gastrointestinal symptoms. The authors state limitations including heterogeneity, observational or small-scale evidence, and limited long-term data.